Genmab AS (GMAB)
21.21
-0.46
(-2.12%)
USD |
NASDAQ |
Nov 14, 16:00
21.21
0.00 (0.00%)
After-Hours: 18:31
Genmab Gross Profit Margin (Quarterly): 95.07% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 95.07% |
| June 30, 2024 | 96.48% |
| March 31, 2024 | 95.53% |
| December 31, 2023 | 97.35% |
| September 30, 2023 | 98.32% |
| June 30, 2023 | 99.50% |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 |
| Date | Value |
|---|---|
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
95.07%
Minimum
Sep 2024
99.50%
Maximum
Jun 2023
97.04%
Average
96.92%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Novo Nordisk AS | 84.14% |
| Ascendis Pharma AS | 68.15% |
| Galecto Inc | -- |
| Evaxion Biotech AS | -- |
| IO Biotech Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 14.86% |
| Return on Assets | 12.66% |
| Return on Invested Capital | 14.86% |
| Profit Margin (Quarterly) | 22.85% |
| Operating Margin (Quarterly) | 38.25% |
| Return on Net Operating Assets | 35.82% |